Experience with intensity-modulated radiotherapy in the treatment of head and neck cancer

被引:0
|
作者
Vanasek, J. [1 ,7 ,8 ]
Odrazka, K. [1 ,8 ]
Dusek, L. [2 ,3 ]
Jarkovsky, J. [2 ,3 ]
Michalek, R. [6 ]
Chrobok, V. [4 ,5 ]
Dolezel, M. [1 ]
Kolarova, I. [1 ,7 ,8 ]
机构
[1] Oncol Ctr Multiscan, Pardubice, Czech Republic
[2] Masaryk Univ, Fac Med, Inst Biostat & Analyses, Brno, Czech Republic
[3] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic
[4] Charles Univ Prague, Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Hradec Kralove, Czech Republic
[5] Charles Univ Prague, Fac Med, Hradec Kralove, Czech Republic
[6] Reg Hosp, Otorhinolaryngol & Head & Neck Surg Clin, Pardubice, Czech Republic
[7] Pardubice Univ, Fac Hlth Studies, Pardubice, Czech Republic
[8] Fac Mil Hlth Sci, Dept Radiobiol, Hradec Kralove, Czech Republic
来源
JOURNAL OF BUON | 2013年 / 18卷 / 04期
关键词
head and neck cancer; IMRT; radiotherapy; relapse; survival; RADIATION-THERAPY; IMRT; PATTERNS; CARCINOMA; FAILURE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Studies using intensity-modulated radiation therapy (IMRT) in the treatment of head and neck tumors have shown to decrease acute and late radiation toxicity. However, the high conformity of this technique can increase the risk of recurrence due to geographic miss. The aim of this study was to analyze whether the results of IMRT met the theoretical expectations concerning treatment efficacy. Methods: From a total of 185 patients (152 males and 33 females, mean age 58+/-10.36 years) 176 were evaluable and were studied. Eighty-nine (48.1%) patients had surgical treatment and 50 of them were scheduled for concomitant cisplatin chemotherapy. Irradiation was performed using IMRT, a sliding window with 9 fields in a Varian 2100 C/D linear accelerator, X-ray beam, 6 MeV. The prescribed dose in the planning treatment volume (PTV1), i.e., the area of the primary tumor and nodal area, was 66 Gy/2.2 Gy-70 Gy/2.12 Gy. In the PTV2 (the area at high risk) the dose was 60Gy/2 Gy-59.4 Gy/ 1.8 Gy, and in the PTV 3 (the area treated with prophylactic irradiation) the prescribed dose was 54 Gy/1.8 Gy-50.4 Gy/1.53 Gy. Results: The 3-year overall survival (OS) and relapse-free survival (RFS) of IMRT-treated patients, most of whom were in stages III and IV (158 out of 177), were 50 and 57%, respectively. Using postoperative radiotherapy/chemoradiotherapy 3-year locoregioncal control was achieved in 75% of the cases as compared with 35% in non-operated patients. Conclusions: The worst outcomes were found in oral cavity and hypopharyngeal tumors, and the best in laryngeal and oropharyngeal tumors. Better results were found in surgically treated patients, and in lower disease stages. Despite the high conformity of dose distribution and efforts to spare healthy tissues, most cases of locoregional relapse occurred in areas receiving the full radiation dose. If dividing relapses into cases of persistence and local recurrence, the former predominated.
引用
收藏
页码:970 / 976
页数:7
相关论文
共 50 条
  • [21] Taste Function in PatientsWith Head and Neck Cancer Receiving Intensity-Modulated Radiotherapy
    Chen, Yi-Tzu
    Chou, Ying-Hsiang
    Wei, James Cheng-Chung
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (12) : 1184 - 1184
  • [22] Intensity-modulated radiotherapy in head and neck cancer - an update for oral and maxillofacial surgeons
    Brennan, P. A.
    Bradley, K. L.
    Brands, M.
    [J]. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2017, 55 (08): : 770 - 774
  • [23] Intensity-modulated radiotherapy of head-and-neck cancer: Encouraging early results
    Eisbruch, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (01): : 1 - 3
  • [24] MARGINAL MISSES AFTER POSTOPERATIVE INTENSITY-MODULATED RADIOTHERAPY FOR HEAD AND NECK CANCER
    Chen, Allen M.
    Farwell, D. Gregory
    Luu, Quang
    Chen, Leon M.
    Vijayakumar, Srinivasan
    Purdy, James A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05): : 1423 - 1429
  • [25] Intensity-modulated radiotherapy in the standard management of head and neck cancer: Promises and pitfalls
    Mendenhall, William M.
    Amdur, Robert J.
    Palta, Jatinder R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (17) : 2618 - 2623
  • [26] Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer
    Schoenfeld, Gordon O.
    Amdur, Robert J.
    Morris, Christopher G.
    Li, Jonathan G.
    Hinerman, Russell W.
    Mendenhall, William M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (02): : 377 - 385
  • [27] Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers
    Bhide, S. A.
    Newbold, K. L.
    Harrington, K. J.
    Nutting, C. M.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2012, 85 (1013): : 487 - 494
  • [28] Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy
    Blake, Claire
    Lai, Rainbow
    Brown, Teresa
    Pelecanos, Anita
    Moroney, Laura
    Helios, Jennifer
    Smith, David
    Hughes, Brett G. M.
    Kenny, Lizbeth
    Chua, Benjamin
    Bauer, Judith
    [J]. JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2024, 37 (01) : 182 - 192
  • [29] Swallowing sparing intensity modulated radiotherapy versus standard parotid sparing intensity-modulated radiotherapy for treatment of head and neck cancer: a randomized clinical trial
    Ashour, May Gamal
    Shouman, Tarek Hamed
    Hassouna, Ashraf Hamed
    Mokhtar, Maha Hassan
    El Din, Reem Emad
    Youssef, Ayda Aly
    Gomaa, Mohammed Mohammed
    Abdelgeleel, Shaimaa
    [J]. ACTA ONCOLOGICA, 2022, 61 (02) : 134 - 140
  • [30] Comparison of intensity-modulated radiotherapy, adaptive radiotherapy proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer
    Simone, Charles B., II
    Ly, David
    Dan, Tu D.
    Ondos, John
    Ning, Holly
    Belard, Arnaud
    O'Connell, John
    Miller, Robert W.
    Simone, Nicole L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 101 (03) : 376 - 382